Xtranet-ISA

Patients are at the heart of the EU’s Innovative Medicines Initiative (IMI) that seeks to speed up the development of more effective and safer medicines. Created in 2008 as a public-private partnership, IMI plays a leading role in the EU’s efforts to remove barriers to the discovery of new treatments. It does this through collaborative research projects and by building networks of industrial, academic experts, researchers, regulators, clinicians and patients.